Journal of Jilin University(Medicine Edition) ›› 2021, Vol. 47 ›› Issue (6): 1518-1525.doi: 10.13481/j.1671-587X.20210623
• Research in clinical medicine • Previous Articles Next Articles
Xiuyan YU,Chunying TIAN,Xiaowei ZHANG,Xuefeng WU()
Received:
2021-03-15
Online:
2021-11-28
Published:
2021-12-14
Contact:
Xuefeng WU
E-mail:22061185@qq.com
CLC Number:
Xiuyan YU,Chunying TIAN,Xiaowei ZHANG,Xuefeng WU. Clinical significances of serum levels of SBEM, hMAM and CEACAM19 in early diagnosis of breast cancer[J].Journal of Jilin University(Medicine Edition), 2021, 47(6): 1518-1525.
Tab.1
Serum levels of SBEM, hMAM, and CEACAM19 of subjects in three groups"
Group | n | SBEM[(ρB/(μg·L-1)] | hMAM[(ρB/(ng·L-1)] | CEACAM19[(ρB/(ng·L-1)] |
---|---|---|---|---|
Healthy control | 54 | 0.63(0.32,1.43) | 106.20(67.45,138.57) | 36.84(21.64,95.88) |
Benign breast disease | 58 | 2.91(1.58,3.78) | 103.10(70.73,158.98) | 49.18(31.59,83.33) |
Breast cancer | 80 | 7.56(4.51,11.30)*△ | 200.63(136.05,275.95)*△ | 86.50(67.28,148.83)*△ |
Tab. 2
Efficiency of SBEM, hMAM, and CEACAM19 levels in serum in diagnosis of breast cancer"
Item | AUC | Sensitivity(η/%) | Specificity(η/%) | Cut-off value | AUC |
---|---|---|---|---|---|
SBEM | 0.868 | 80.0 | 88.4 | 4.05 μg·L-1 | 0.809-0.926 |
hMAM | 0.809 | 70.0 | 80.4 | 158.87 μg·L-1 | 0.747-0.871 |
CEACAM19 | 0.756 | 97.5 | 50.9 | 48.23 μg·L-1 | 0.689-0.823 |
SBEM+hMAM+CEACAM19 | 0.913 | 82.5 | 90.2 | - | 0.869-0.958 |
Tab. 3
Relationships between levels of SBEM, hMAM,and CEACAM19 in serum and clinicopathological parameters of breast cancer patients"
Clinicopathological feature | n | SBEM[ρB/(μg·L-1)] | Z/P | hMAM[ρB/(ng·L-1)] | Z/P | CEACAM19[ρB/(ng·L-1)] | Z/P |
---|---|---|---|---|---|---|---|
Age(year) | |||||||
≤50 | 35 | 7.58(4.14,14.33) | 0.524/0.600 | 200.86(117.83,282.30) | 0.301/0.764 | 97.70(71.70,150.60) | 0.698/0.485 |
>50 | 45 | 7.54(4.82,10.82) | 198.45(147.29,273.34) | 82.80(63.29,149.83) | |||
Maximum tumor size (l/cm) | |||||||
≤2 | 43 | 6.79(3.33,10.75) | 1.882/0.060 | 179.85(119.86,263.00) | 1.501/0.133 | 78.40(59.50,112.20) | 2.186/0.029 |
>2 | 37 | 10.41(4.97,13.81) | 206.62(147.29,288.56) | 99.80(73.26,159.50) | |||
TNM stage | |||||||
Ⅰ-Ⅱ | 80 | 6.42(3.21,10.63) | 5.420/<0.001 | 168.99(116.50,249.93) | 3.621/<0.001 | 76.69(60.23,98.11) | 4.903/<0.001 |
Ⅲ-Ⅳ | 22 | 15.35(10.57,22.67) | 262.36(200.26,294.90) | 155.33(113.18,183.98) | |||
Lymphnode metastasis | |||||||
Yes | 45 | 5.59(2.27,10.69) | 3.283/0.001 | 175.83(118.84,267.18) | 1.989/0.048 | 82.50(68.47,100.90) | 1.999/0.045 |
No | 35 | 10.68(6.86,17.01) | 238.63(168.99,284.03) | 142.20(67.20,164.50) | |||
ER | |||||||
Negtive | 16 | 9.15(6.86,10.57) | 0.217/0.829 | 161.24(107.36,194.19) | 0.210/0.833 | 78.28(68.71,146.91) | 0.932/0.351 |
Positive | 64 | 11.41(5.85,14.40) | 192.58(119.35,225.65) | 79.64(63.29,163.77) | |||
PR | |||||||
Negtive | 20 | 7.88(6.75,10.52) | 0.372/0.710 | 187.60(114.73,193.80) | 0.622/0.534 | 72.24(61.68,126.05) | 0.022/0.982 |
Positive | 60 | 12.40(5.28,14.58) | 197.55(118.84,245.11) | 82.80(65.25,164.01) | |||
Her-2 | |||||||
Negtive | 64 | 10.52(6.45,14.12) | 0.427/0.669 | 179.07(118.34,206.08) | 0.872/0.383 | 83.57(67.93,164.26) | 0.577/0.564 |
Positive | 16 | 8.70(6.99,10.41) | 191.09(187.60,194.57) | 61.68(55.83,67.53) | |||
Ki-67 | |||||||
Negtive | 14 | 10.32(6.42,14.23) | 1.488/0.137 | 83.66(49.50,117.83) | 1.557/0.119 | 65.25(63.29,67.20) | 0.798/0.425 |
Positive | 66 | 10.41(6.64,13.46) | 193.80(123.77,206.08) | 83.57(68.18,164.26) | |||
AR | |||||||
Negtive | 6 | 7.20(6.52,7.88) | 0.845/0.398 | 114.73(100.00,129.46) | 0.804/0.422 | 78.28(72.24,84.33) | 0.124/0.902 |
Positive | 31 | 10.52(6.56,14.12) | 193.80(120.36,206.08) | 79.64(64.27,164.26) | |||
P53 | |||||||
Negtive | 20 | 10.41(3.73,13.31) | 1.102/0.270 | 193.02(115.17,201.65) | 1.365/0.172 | 67.53(63.29,120.49) | 2.520/0.012 |
Positive | 14 | 10.41(7.44,14.36) | 187.60(124.66,314.81) | 89.00(77.52,166.71) | |||
EGFR | |||||||
Negtive | 21 | 10.52(6.87,14.40) | 1.606/0.108 | 190.31(119.35,205.86) | 0.887/0.375 | 80.40(66.47,163.77) | 0.571/0.568 |
Positive | 10 | 7.45(1.67,11.44) | 160.16(67.59,345.41) | 75.00(64.27,229.64) | |||
P63 | |||||||
Negtive | 28 | 7.71(4.73,11.27) | 0.913/0.361 | 163.81(113.85,203.70) | 0.723/0.470 | 77.41(63.29,127.13) | 1.104/0.270 |
Positive | 8 | 11.69(4.74,16.08) | 234.91(97.09,280.53) | 96.61(70.37,178.54) |
1 | ZISI Z, ADAMOPOULOS P G, KONTOS C K, et al. Identification and expression analysis of novel splice variants of the human carcinoembryonic antigen-related cell adhesion molecule 19 (CEACAM19) gene using a high-throughput sequencing approach[J]. Genomics, 2020, 112(6): 4268-4276. |
2 | MICHAELIDOU K, TZOVARAS A, MISSITZIS I, et al. The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression[J].Int J Oncol, 2013,42(5):1770-1777. |
3 | ESTIAR M A, ESMAEILI R, ZARE A A, et al. High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer[J]. Clin Exp Med, 2017, 17(4): 547-553. |
4 | MIKSICEK R J, MYAL Y, WATSON P H, et al. Identification of a novel breast-and salivary gland-specific, mucin-like gene strongly expressed in normal and tumor human mammary epithelium[J]. Cancer Res, 2002, 62(10): 2736-2740. |
5 | LI Q H, LIU Z Z, GE Y A, et al. Small breast epithelial mucin promotes the invasion and metastasis of breast cancer cells via promoting epithelial‑to‑mesenchymal transition[J]. Oncol Rep, 2020, 44(2): 509-518. |
6 | ZHANG Y Q, LUN X Q, GUO W L. Expression of TRPC1 and SBEM protein in breast cancer tissue and its relationship with clinicopathological features and prognosis of patients[J]. Oncol Lett, 2020, 20(6): 392. |
7 | KIM S W, GOEDEGEBUURE P, GILLANDERS W E.Mammaglobin-A is a target for breast cancer vaccination[J].Oncoimmunology,2016,5(2):e1069940. |
8 | OLOOMI M, MOAZZEZY N, BOUZARI S. Modulation of molecular biomarker expression in response to chemotherapy in invasive ductal carcinoma[J]. Biomed Res Int, 2018, 2018: 7154708. |
9 | NGUYEN H M, DAO M Q. Detection of human mammaglobin mRNA in breast cancer cells among Vietnamese women[J]. Breast Cancer (Dove Med Press), 2019, 11: 143-150. |
10 | BAKER L, HALL L, WILSON D, et al. Plasma levels of mammaglobin-A, VEGF and PlGF in human breast cancer pathology and survival[J]. Eur J Surg Oncol, 2019, 45(2): e40. |
11 | GHASEMI-DEHKORDI P, DOOSTI A, JAMI M S. The functions of azurin of Pseudomonas aeruginosa and human mammaglobin-A on proapoptotic and cell cycle regulatory genes expression in the MCF-7 breast cancer cell line[J]. Saudi J Biol Sci, 2020, 27(9): 2308-2317. |
12 | 崔云会, 陈 楠, 王云龙, 等. 人乳腺珠蛋白荧光免疫层析检测方法的建立[J].中国免疫学杂志,2021,37(8): 975-978. |
13 | 于秀艳, 张晓伟, 野丽莉, 等. hMAM联合MMP-9和C-erbB2 mRNA表达检测在乳腺癌外周血微转移诊断中的应用[J].吉林大学学报(医学版),2017,43(5):1009-1014. |
14 | 于秀艳, 张晓伟, 丛占杰,等. 乳腺癌患者血清中hMAM和CD147水平检测及其临床意义[J]. 吉林大学学报(医学版), 2018, 44(6): 1269-1274. |
15 | 乳腺癌雌、孕激素受体免疫组织化学检测指南编写组. 乳腺癌雌、孕激素受体免疫组织化学检测指南 [J].中华病理学杂志,2015,44(4): 237-239. |
16 | 《乳腺癌HER检测指南》编写组, 霍临明. 乳腺癌HER2检测指南[J]. 中华病理学杂志,2006,35(10): 631-633. |
17 | 许良中, 杨文涛. 免疫组织化学反应结果的判断标准[J]. 中国癌症杂志, 1996, 6(4):229-231. |
18 | CASTELLANO I, ALLIA E, ACCORTANZO V,et al.Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers[J]. Breast Cancer Res Treat, 2010, 124(3): 607-617. |
19 | NIELL B L, FREER P E, WEINFURTNER R J,et al. Screening for breast cancer[J]. Radiol Clin North Am, 2017, 55(6): 1145-1162. |
20 | BRITT K L, CUZICK J, PHILLIPS K A. Key steps for effective breast cancer prevention[J]. Nat Rev Cancer, 2020, 20(8): 417-436. |
21 | CHEN I X, CHAUHAN V P, POSADA J, et al. Blocking CXR4 alleviates desmoplasia,increases T-lymphocyte infltration,and improves immunotherapy in meta-static breast cancer[J].Proc Natl Acad Sci U S A,2019,116(10):4558-4566. |
22 | BAKER E, WHITEOAK N, HALL L, et al. Mammaglobin-A, VEGFR3, and Ki67 in human breast cancer pathology and five year survival[J]. Breast Cancer, 2019, 13: 1178223419858957. |
23 | MILOSEVIC M, JANKOVIC D, MILENKOVIC A, et al. Early diagnosis and detection of breast cancer[J]. Technol Heal Care, 2018, 26(4): 729-759. |
24 | KELLEHER M, SINGH R, O'DRISCOLL C M,et al. Carcinoembryonic antigen (CEACAM) family members and Inflammatory Bowel Disease[J]. Cytokine Growth Factor Rev, 2019, 47: 21-31. |
25 | JOUDI F SAL. Human mammaglobin in breast cancer: a brief review of its clinical utility[J]. Indian J Med Res, 2014, 139(5): 675-685. |
26 | SKLIRIS G P, HUBÉ F, GHEORGHIU I, et al. Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers[J].Histopathology,2008,52(3):355-369. |
27 | 于洪涛, 唐大海. 癌胚抗原相关细胞粘附因子19与乳腺癌相关基因关系[J]. 中国公共卫生, 2016, 32(1): 105-107. |
28 | LI J, XU W W, ZHU Y X. Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer[J]. Oncol Lett, 2020, 20(5): 255. |
29 | 卢达新,高艳霞,于丽凤,等.微小RNA hsa-mir-301b对乳腺癌细胞增殖能力的影响研究[J].中国实用内科杂志,2021,41(2):141-145. |
30 | ZHAO H, XU J, WANG Y, et al. Knockdown of CEACAM19 suppresses human gastric cancer through inhibition of PI3K/Akt and NF-κB[J]. Surg Oncol, 2018, 27(3): 495-502. |
[1] | Xiuyan YU,Ting LI,Zhanjie CONG,Wenlong WANG,Xiaowei ZHANG,Xuefeng WU. Combined detection of hMAM, SBEM and CEACAM19 mRNA in peripheral blood of breast cancer patients and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2022, 48(1): 195-202. |
[2] | Yang YU,Sainan LIU,Yunkai LIU,Yong LI,Yichun QIAO,Yi CHENG. Bioinformatic analysis on expression characteristics of PRPS2 and its relationship with prognosis of breast cancer [J]. Journal of Jilin University(Medicine Edition), 2021, 47(5): 1229-1236. |
[3] | Qing WANG,Siqi XIE,Kai ZHENG,Yiyin TANG,Hongwan LI,Hengyu ZHANG,Mingjian TAN,Lei PENG,Dequan LIU,Shicong TANG. Detection of serum vitamin-B levels in breast cancer patients receiving different chemotherapy regimens and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 724-730. |
[4] | Haoxuan TANG,Nanfeng MENG,Meiling DU,Wei WANG,Tao HE. Inhibitory effect of new VEGF monoclonal antibody combined with all-trans retinoic acid on proliferation of breast cancer MCF-7 cells [J]. Journal of Jilin University(Medicine Edition), 2021, 47(2): 344-351. |
[5] | KONG Wencong, HE Wubin, SU Rongjian, JIA Daqi, GU Yanjiao, WANG Yue, DU Xiaoyuan. Inhibitory effect and apoptosisinduction of MST1R inhibitor BMS-777607 on proliferation of breast cancer MCF-7 cells [J]. Journal of Jilin University(Medicine Edition), 2020, 46(03): 451-457. |
[6] | CHEN Zhouhua, GONG Hui, FENG Lei, XIAO Yujie, HUANG Lizhong. Induction of LPS on epithelial mesenchymal transition in breast cancer MDA-MB-231 cells and its effect on β-catenin expression [J]. Journal of Jilin University(Medicine Edition), 2020, 46(02): 309-315. |
[7] | ZHOU Chun, WANG Guanghua, ZHANG Bangzhu. Effects of miR-367 on proliferation, invasion and migration of human breast cancer MCF-7 cells and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1353-1360. |
[8] | YANG Zhuangqing, LU Mei, YANG Xiaojuan, WANG Chang'an, ZOU Jieya. Inhibitory effect of inhibiting TRIM24 gene expression on proliferation, apopotosis,invasion and migration of breast cancer MCF-7 cells [J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1379-1383. |
[9] | YUE Yuan, XU Yinglian, WANG Jingjing, SUN Minying, ZHANG Zenan, ZHAO Xinyue, LI Zongpu, TAI Guixiang. Inhibitory effects of down-regulation of JNK enzymatic activity on growth of human prostate cancer cells, hepatocellular carcinoma cells and breast cancer cells [J]. Journal of Jilin University(Medicine Edition), 2019, 45(05): 1046-1051. |
[10] | YU Xiuyan, WAN Guangcai, SUN Hongshuai, ZHU Hua, GAO Haiyan, WU Xuefeng. Relationship between fibrinogen and prognosis of breast cancer patients:A Meta-analysis [J]. Journal of Jilin University(Medicine Edition), 2019, 45(05): 1092-1097. |
[11] | TAN Qi, REN Liqun, ZHANG Yibing, WANG Yadi, GU Zehui, HUANG Peng, CHEN Suxian. Application of bioinformatics in screening of miRNA biomarkers in triple-negative breast cancer [J]. Journal of Jilin University(Medicine Edition), 2019, 45(05): 1098-1105. |
[12] | WANG Shuang, KANG Lihua, GUAN Meng, WANG Lei, LI Beibei, ZHAO Yue, SONG Yanqiu, YANG Tingting. Clinical application of apatinib mesylate combined with chemotherapy in treatment of patients with advanced breast cancer [J]. Journal of Jilin University(Medicine Edition), 2019, 45(05): 1152-1158. |
[13] | XIN Rui, LI Dong, XU Huiying, WANG Chunyu, QU Danhua, SUN Haifeng. Influence of miRNA-21 in radiosensitivity of breast cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2019, 45(04): 772-778. |
[14] | ZHOU Hongxu, DU Ye, YU Yunhe, HAN Bing, LI Sijie, GUO Guoqiang, FAN Zhimin. Discordance for hormone receptors and Her-2 expressions in primary lesion and ipsilateral axillary lymph node metastasis of breast cancer and its influence in prognosis [J]. Journal of Jilin University(Medicine Edition), 2019, 45(02): 376-382. |
[15] | SHANG Yanhong, PAN Yuchen, JIA Zhifang, WANG Yueqi, YANG Na, ZHAO Dan, JIANG Jing. Detection of expression levels of miR200 family in plasma of breast cancer patients and its significance [J]. Journal of Jilin University(Medicine Edition), 2019, 45(02): 383-388. |